Studies investigating the impact of donor cytomegalovirus (CMV) positivity on the prognosis of liver transplantation (LT) recipients with HCC are currently lacking. A total of 21 759 eligible LT recipients were identified in the UNOS database between January 2002 and June 2023. The patients were divided into the donor CMV-seronegative (n = 7575) and CMV-seropositive (n = 14 814) groups. Moreover, the subgroup analyses by recipient age and gender were conducted. All patients were also divided into 18-40 (n = 271), 40-60 (n = 9538), and ≥ 60 (n = 11 950) groups, male (n = 16 954) and female (n = 4805) groups, respectively. Patients in the donor CMV-seropositive group had shorter overall survival (OS) and disease-free survival (DFS) compared to those in the donor CMV-seronegative group (both p < 0.001). Donor CMV seropositivity was proved to be a risk factor for OS and DFS (both p = 0.001). Patients receiving CMV-seropositive liver grafts had shorter OS and DFS in the 40-60 and ≥ 60 groups (all p < 0.05). Patients receiving CMV-seropositive liver grafts had shorted OS and DFS only in the male group (both p < 0.001). The receipt of donor CMV-seropositive liver grafts is associated with shorter survival and a higher risk of HCC recurrence in LT recipients with HCC. These adverse effects are influenced by recipient age and gender.
Keywords: donor cytomegalovirus seropositivity; hepatocellular carcinoma; liver transplantation; recurrence; survival.
© 2025 Wiley Periodicals LLC.